Generic Ivra Availability
Last updated on Jun 11, 2025.
Ivra is a brand name of melphalan, approved by the FDA in the following formulation(s):
IVRA (melphalan hydrochloride - solution;intravenous)
-
Manufacturer: APOTEX
Approval date: August 18, 2023
Strength(s): EQ 90MG BASE/ML (EQ 90MG BASE/ML) [RLD]
Is there a generic version of Ivra available?
No. There is currently no therapeutically equivalent version of Ivra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ivra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stable liquid formulations of melphalan
Patent 10,537,520
Issued: January 21, 2020
Inventor(s): Chandrashekhar Kocherlakota & Nagaraju Banda
Assignee(s): LEIUTIS PHARMACEUTICALS PVT. LTD.The present invention relates to stable, liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.
Patent expiration dates:
- June 29, 2036✓
- June 29, 2036
More about Ivra (melphalan)
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Pomalyst
Pomalyst (pomalidomide) is used to treat multiple myeloma and AIDS-related Kaposi sarcoma. Includes ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.